Antidepressants are the current pharmacotherapy go-to for postpartum depression (PPD) despite their slow action and frequent failure to induce remission. Now, a new PPD treatment option may be on the horizon. In a recent phase 3 trial, women with PPD had rapid reductions in depression symptoms after a 2-week course of daily oral zuranolone, a novel neuroactive steroid γ-aminobutyric acid receptor–positive allosteric modulator.
Slomski A. Novel Oral Drug Rapidly Treats Postpartum Depression. JAMA. 2021;326(9):800. doi:10.1001/jama.2021.14708
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: